CD19-targeted CAR-T cells therapy (Sinobioway Cell Therapy)

N/A

Report date: 2026/01/27 20:00:10

Base Information

Drug NameCD19-targeted CAR-T cells therapy (Sinobioway Cell Therapy)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsT lymphocyte replacements
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsLeukemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesSinobioway Cell Therapy Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesSinobioway Cell Therapy Co Ltd
Inactive CompaniesN/A
Active IndicationsLeukemia
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A